Proto Script Pharmaceutical Corp.
PSCR · OTC
12/31/2016 | 12/31/2015 | 5/31/2014 | 5/31/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.24 | -13.36 | 34.17 |
| FCF Yield | 0.03% | 0.34% | -0.35% | -0.35% |
| EV / EBITDA | -301.49 | -131.61 | -205.76 | -240.42 |
| Quality | ||||
| ROIC | 111.04% | -149.07% | 136.51% | -116.29% |
| Gross Margin | 71.55% | 78.77% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.01 | -0.26 | 0.85 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -9.78% | 198.48% | -1.52% | -34.92% |
| Safety | ||||
| Net Debt / EBITDA | -0.16 | -0.38 | 0.00 | 0.92 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -191.30 | 25.38 | 0.00 | 0.00 |